Top

Published in:

01-03-2010

Topical Antibiotic Therapy of Chronic Rhinosinusitis

Authors: Richard H. Comstock III, Kent Lam, Suzette Mikula

Published in: Current Infectious Disease Reports | Issue 2/2010

Abstract

Many different treatment options for chronic rhinosinusitis (CRS) exist, but questions remain regarding the best options. Although oral and intravenous antimicrobial therapies have traditionally been prescribed to manage CRS, topical administration of these agents has gained increasing popularity over the past few years. Topical antimicrobial agents are preferable because of their ability to localize delivery to the sinonasal mucosa and minimize the systemic effects seen with oral agents. This quality is especially important in treatment of biofilms, where higher concentrations of antibiotics are usually required. This article gives a brief overview of CRS and provides a summary of recent studies using topical agents for treatment of bacterial and fungal sinusitis.

Bhattacharyya N: The economic burden and symptom manifestations of chronic rhinosinusitis. Am J Rhinol 2003, 17:27–32.PubMed

Wasan A, Fernandez E, Jamison RN, et al.: Association of anxiety and depression with reported disease severity in patients undergoing evaluation for chronic rhinosinusitis. Ann Otol Rhinol Laryngol 2007, 116:491–497.PubMed

•• Rosenfeld RM, Andes D, Bhattacharyya N, et al.: Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg 2007, 137:S1–S31. This article, written by a panel selected by the American Academy of Otolaryngology-Head and Neck Surgery, provides a comprehensive guideline with recent evidence-based recommendations on the diagnosis and management of acute and chronic forms of rhinosinusitis in adult populations.CrossRefPubMed

Benninger MS, Ferguson BJ, Hadley JA, et al.: Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology and pathophysiology. Otolaryngol Head Neck Surg 2003, 129(3 Suppl):S1–S32.CrossRefPubMed

Chan Y, Kuhn FA: An update on the classifications, diagnosis, and treatment of rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 2009, 17:204–208.CrossRefPubMed

Sharp HJ, Denman D, Puumala S, et al.: Treatment of acute and chronic rhinosinusitis in the United States, 1999–2002. Arch Otolaryngol Head Neck Surg 2007, 133:260–265.CrossRefPubMed

Burton MJ, Eisenberg LD, Rosenfeld RM: Extracts from The Cochrane Library: nasal saline irrigations for the symptoms of chronic rhinosinusitis. Otolaryngol Head Neck Surg 2007, 137:532–534.CrossRefPubMed

Aukuma A, Mulder P, Fokkens W: Treatment of nasal polyposis and chronic rhinosinusitis with fluticasone propionate nasal drops reduces need for sinus surgery. J Allergy Clin Immunol 2005, 115:1017–1023.CrossRef

Osguthorpe JD: Surgical outcomes in rhinosinusitis: what we know. Otolaryngol Head Neck Surg 1999, 120:451–453.CrossRefPubMed

10.

Bhattacharyya N: Clinical outcomes after endoscopic sinus surgery. Curr Opin Allergy Clin Immunol 2006, 6:167–171.CrossRefPubMed

11.

• Hilton C, Wiedmann T, St. Martin M, et al.: Differential deposition of aerosols in the maxillary sinus of human cadavers by particle size. Am J Rhinol 2008, 22:395–398. This research analyzed the delivery of nebulized particles in the paranasal sinuses of four human cadavers, and found that particle size and nasal anatomy were both contributing factors that affected the deposition of particles into the maxillary sinus.CrossRefPubMed

12.

Goh YH, Goode RL: Current status of topical nasal antimicrobial agents. Laryngoscope 2000, 110:875–880.CrossRefPubMed

13.

Mahoney EJ, Metson R: Palliative care for the patient with refractory chronic rhinosinusitis. Otolaryngol Clin North Am 2009, 42:39–47, vii–viii.CrossRefPubMed

14.

Davis LJB, Kita H: Pathogenesis of chronic rhinosinusitis: role of airborne fungi and bacteria. Immunol Allergy Clin North Am 2004, 24:59–73.CrossRefPubMed

15.

Brook I: The role of bacteria in chronic rhinosinusitis. Otolaryngol Clin North Am 2005, 38:1171–1192.CrossRefPubMed

16.

Sanclement JA, Webster P, Thomas J, Ramadan HH: Bacterial biofilms in surgical specimens of patients with chronic rhinosinusitis. Laryngoscope 2005, 115:578–582.PubMed

17.

Sanderson AR, Leid JG, Hunsaker D: Bacterial biofilms on the sinus mucosa of human subjects with chronic rhinosinusitis. Laryngoscope 2006, 116:1121–1126.CrossRefPubMed

18.

• Post JC, Hiller NL, Nistico L et al.: The role of biofilms in otolaryngologic infections: update 2007. Curr Opin Otolaryngol Head Neck Surg 2007, 15:347–351. This review article highlights current understanding of bacterial biofilm and its impact in the pathogenesis of different head and neck infections.CrossRefPubMed

19.

Ramadan HH, Sanclement JA, Thomas JG: Chronic rhinosinusitis and biofilms. Otolaryngol Head Neck Surgery 2005, 132:414–417.CrossRef

20.

Seiberling KA, Grammer L, Kern RC: Chronic rhinosinusitis and superantigens. Otolaryngol Clin North Am 2005, 38:1215–1236.CrossRefPubMed

21.

Ferguson BJ: Categorization of eosinophilic chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg 2004, 12:237–242.CrossRefPubMed

22.

Gosepath J, Mann WJ: Role of fungus in eosinophilic sinusitis. Curr Opin Otolaryngol Head Neck Surg 2005, 13:9–13.CrossRefPubMed

23.

Ponikau JU, Sherris DA, Kern EB, et al.: The diagnosis and incidence of allergic fungal sinusitis. Mayo Clin Proc 1999, 74:877–884.CrossRefPubMed

24.

Dinis PB, Monteiro MC, Lobato R, et al.: Penetration of cefuroxime into chronically inflamed sinus mucosa. Laryngoscope 1999, 109:1841–1847.CrossRefPubMed

25.

Dinis PB, Monteiro MC, Martins ML, et al.: Soft tissue pharmacokinetics after oral administration of amoxicillin/clavulanic acid. Laryngoscope 2000, 110:1050–1055.CrossRefPubMed

26.

Hardy JG, Lee SW, Wilson CG: Intranasal drug delivery by spray and drops. J Pharm Pharmacol 1985, 37:294–297.PubMed

27.

Aoki FY, Crawley JCW: Distribution and removal of human albumin-technetium 99 m instilled intransally. J Pharm Pharmacol 1976, 3:869–878.

28.

Lim M, Citardi MJ, Leong JL: Topical antimicrobials in the management of chronic rhinosinusitis: A systematic review. Am J Rhinol 2008, 22:381–389.CrossRefPubMed

29.

Suman JD, Laube BL, Dalby R: Comparison of nasal deposition and clearance of aerosol generated by nebulizer and an aqueous spray pump. J Aerosol Med 2006, 19:510–521.CrossRefPubMed

30.

•• Uren B, Psaltis A, Wormald PJ: Nasal lavage with mupirocin for the treatment of surgically recalcitrant chronic rhinosinusitis. Laryngoscope 2008, 118:1677–1680. This study determined that mupirocin appears to be an effective means of treatment for postsurgical patients with S. aureus-positive exacerbations of their disease.CrossRefPubMed

31.

Aerosol Science Laboratory, ASL Pharmacy: Nebulized sinus medications. Available at http://www.aslrx.com. Accessed October 2009

32.

Ponikau JU, Sherris DA, Kita H: Intranasal antifungal treatment in 51 patients with chronic rhinosinusitis. J Allergy Clin Immunol 2002, 110:862–866.CrossRefPubMed

33.

Weschta M, Rimek D, Formanek M, et al.: Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: a randomized, double-blind clinical trial. J Allergy Clin Immunol 2004, 113:1122–1128.CrossRefPubMed

34.

Helbling A, Baumann A, Hanni C, Caversaccio M: Amphotericin B nasal spray has no effects on nasal polyps. J Laryngol Otol 2006, 120:1023–1025.CrossRefPubMed

35.

Ponikau JU, Sherris DA, Weaver A, Kita H: Treatment of chronic rhinosinusitis with intranasal amphotericin B: a randomized, placebo-controlled, double-blind pilot trial. J Allergy Clin Immunol 2005, 115:125–131.CrossRefPubMed

36.

•• Ebbens FA, Scadding GK, Badia L, et al.: Amphotericin B nasal lavages: not a solution for patients with chronic rhinosinusitis. J Allergy Clin Immunol 2006, 118:1149–1156. This prospective, placebo-controlled, double-blind study showed no statistical difference between amphotericin and placebo in both subjective and objective measures.CrossRefPubMed

37.

Shirazi MA, Stankiewicz JA, Kammeyer P: Activity of nasal amphotericin B irrigation against fungal organisms in vitro. Am J Rhinol 2007, 21:145–148.CrossRefPubMed

38.

Desrosiers M, Bendouah Z, Barbeau J: Effectiveness of topical antibiotics on Staphylococcus aureus biofilm in vitro. Am J Rhinol 2007, 21:149–153.CrossRefPubMed

39.

•• Ha KR, Psaltis AJ, Butcher AR, et al.: In vitro activity of mupirocin on clinical isolated of Staphylococcus aureus and its potential implications in chronic rhinosinusitis. Laryngoscope 2008, 118:535–540. In this in vitro study comparing the efficacy of mupirocin, ciprofloxacin, and vancomycin on S. aureus biofilms, the authors determined that mupirocin was the only suitable choice for intranasal delivery because of its efficacy and lack of potential side effects.CrossRefPubMed

40.

Nadel DM, Lanza DC, Kennedy DW: Endoscopically guided sinus cultures in normal subjects. Am J Rhinol 1999, 13:87–90.CrossRefPubMed

41.

Ceri H, Olson ME, Stremick C, et al.: The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999, 37:1771–1776.PubMed

42.

• Chiu AG, Antunes MB, Plamer JN, et al.: Evaluation of the in vivo efficacy of topical tobramycin against Pseudomonas sinonasal biofilms. J Antimicro Chemo 2007, 59:1130–1134. This in vivo study performed in a rabbit model found that topical tobramycin was ineffective in eradicating Pseudomonas biofilms.CrossRef

43.

Scheinberg PA, Otsuji A: Nebulized antibiotics for the treatment of acute exacerbations of chronic rhinosinusitis. Ear Nose Throat J 2002, 81:648–652.PubMed

44.

Vaughan WC, Carvalho G: Use of nebulized antibiotics for acute infections in chronic sinusitis. Otolaryngol Head Neck Surg 2002, 127:558–568.CrossRefPubMed

45.

• Desrosiers MY, Salas-Prato M: Treatment of chronic rhinosinusitis refractory to other treatments with topical antibiotic therapy delivered by means of a large-particle nebulizer: results of a controlled trial. Otol Head Neck Surg 2001, 125:265–269. This study found no statistical difference between saline irrigation and tobramycin irrigation in regards to quality of life, symptoms, and endoscopy findings.CrossRef

Title: Topical Antibiotic Therapy of Chronic Rhinosinusitis
Authors: Richard H. Comstock III
Kent Lam
Suzette Mikula
Publication date: 01-03-2010
Publisher: Current Science Inc.
Published in: Current Infectious Disease Reports / Issue 2/2010
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-010-0085-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

The Next Era of HCV Antiviral Therapy Finally Begins: Part 1

Partner Concurrency and the STD/HIV Epidemic

Evaluation and Management of Anal Intraepithelial Neoplasia in HIV-Negative and HIV-Positive Men Who Have Sex with Men

The Role of Adenovirus in Respiratory Tract Infections

The Next Era of HCV Antiviral Therapy Finally Begins: Part 2

Recent Advances in the Understanding and Management of Kawasaki Disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials